Holen Sie sich die Stockscreener-App
187.69
0.81%
-1.54
Handel nachbörslich:
187.69
Schlusskurs vom Vortag:
$189.23
Offen:
$186.92
24-Stunden-Volumen:
287.58K
Relative Volume:
0.94
Marktkapitalisierung:
$19.94B
Einnahmen:
$3.10B
Nettoeinkommen (Verlust:
$-523.70M
KGV:
-11.24
EPS:
-16.6978
Netto-Cashflow:
$-1.36B
1W Leistung:
-8.46%
1M Leistung:
-14.29%
6M Leistung:
+8.59%
1J Leistung:
+0.43%
1-Tages-Spanne:
$184.49
$188.32
1-Wochen-Bereich:
$184.49
$203.00
52-Wochen-Spanne:
$126.97
$248.16
Beigene Ltd Adr Stock (BGNE) Company Profile
Firmenname
Beigene Ltd Adr
Sektor
Branche
Telefon
13459494123
Adresse
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
Vergleichen Sie BGNE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| BGNE | 187.69 | 19.94B | 3.10B | -523.70M | -1.36B | -16.70 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Beigene Ltd Adr Stock (BGNE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-06 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-12 | Eingeleitet | Macquarie | Outperform |
| 2023-08-17 | Eingeleitet | Jefferies | Buy |
| 2023-07-17 | Eingeleitet | Citigroup | Buy |
| 2023-06-30 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | Eingeleitet | Daiwa Securities | Buy |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-10-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | Fortgesetzt | JP Morgan | Overweight |
| 2022-03-17 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | Eingeleitet | Deutsche Bank | Buy |
| 2021-10-12 | Eingeleitet | Bernstein | Outperform |
| 2021-10-06 | Hochstufung | CLSA | Underperform → Buy |
| 2021-03-08 | Eingeleitet | China Renaissance | Buy |
| 2021-03-01 | Herabstufung | CLSA | Outperform → Underperform |
| 2020-11-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-11-06 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2020-07-10 | Herabstufung | CLSA | Buy → Outperform |
| 2020-03-13 | Hochstufung | Macquarie | Underperform → Neutral |
| 2020-02-18 | Fortgesetzt | Goldman | Buy |
| 2020-01-17 | Hochstufung | CLSA | Outperform → Buy |
| 2020-01-17 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-12-16 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-12-16 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-11-19 | Herabstufung | UBS | Buy → Neutral |
| 2019-11-13 | Herabstufung | CLSA | Buy → Outperform |
| 2019-11-04 | Bestätigt | Maxim Group | Buy |
| 2019-06-04 | Eingeleitet | Bernstein | Outperform |
| 2019-05-10 | Hochstufung | CLSA | Outperform → Buy |
| 2019-03-15 | Eingeleitet | BofA/Merrill | Buy |
| 2019-01-04 | Herabstufung | CLSA | Buy → Outperform |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-25 | Eingeleitet | Leerink Partners | Outperform |
| 2018-05-17 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Beigene Ltd Adr Aktie (BGNE) Neueste Nachrichten
BeiGene announces name change to BeOne Medicines Ltd. - Investing.com
BeiGene shares lift on raised price target to $260 from $254 - Investing.com
UBS Raises BeiGene (BGNE.US) TP to US$289.7 as 3Q Results Beat - AASTOCKS.com
BeiGene shares fall despite better-than-expected Q3 results - Investing.com
BeiGene shares fall despite better-than-expected Q3 results By Investing.com - Investing.com UK
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting - GlobeNewswire Inc.
BeiGene announces passing of board member Donald Glazer - Investing.com
BEIGENE Senior Staff Reportedly Investigated, but Not Related to Firm Operations - AASTOCKS.com
Indaptus Therapeutics partners with BeiGene for cancer study - Investing.com India
BeiGene stock momentum builds on Brukinsa success, says JPMorgan's Fye - Investing.com
CMBI Eyes Opportunities in Innovative Medical Insurance, Prefers WuXi AppTec/ BeiGene/ INNOVENT BIO/ SKB BIO-B/ GIANT BIOGENE/ 3SBIO/ Mindray Bio-MedicalUS StocksGlobal News Content - AASTOCKS.com
Financial Fitness Check: Examining BeiGene Ltd ADR (BGNE)’s Key Ratios - The Dwinnex
The Potential Rise in the Price of BeiGene Ltd ADR (BGNE) following insiders activity - Knox Daily
Samsara Inc (IOT) may enjoy gains as insiders got busy in the recent days - Knox Daily
Monitoring Ginkgo Bioworks Holdings Inc (DNA) after recent insider movements - Knox Daily
Insider Sale Alert: PepsiCo Inc [PEP] – Is it Time to sell? - Knox Daily
VZIO (VIZIO Holding Corp) may reap gains as insiders became active recently - Knox Daily
Investing in Allegro Microsystems Inc. (ALGM) Is Getting More Attractive - Knox Daily
Investing in Alphatec Holdings Inc (ATEC): What You Must Know - Knox Daily
An Analysis of Mercury Systems Inc (MRCY)’s Potential Price Growth - Knox Daily
XPeng Inc. Sponsored ADR (XPEV) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
BeiGene CEO John Oyler sells shares worth over $3.75 million - Investing.com
Royal Caribbean Group [RCL] Shares Rise 5.26 % on Wednesday - Knox Daily
Selling Buzz: UL Solutions Inc [ULS] 10% Owner ULSE Inc. sells 3,000,000 shares of the company - Knox Daily
Director Cui Xiangmin acquire 277,895 shares of Nuvation Bio Inc [NUVB] - Knox Daily
Taking a look at what insiders are doing to gauge the BeiGene Ltd ADR (BGNE)’s direction - Knox Daily
Stock Performance Spotlight: BeiGene Ltd ADR (BGNE) Ends the Day at 240.40, Up by 2.11 - The Dwinnex
Buying Buzz: Vuzix Corporation [VUZI] Director Harned Timothy Heydenreich purchases 20,000 shares of the company - Knox Daily
A company insider recently sold 1,447 shares of uniQure N.V. [QURE]. Should You Sale? - Knox Daily
Director Stark Eugene S acquire 2,500 shares of Prospect Capital Corp [PSEC] - Knox Daily
It makes sense and dollars to buy BeiGene Ltd ADR (BGNE) stock - SETE News
Recent Insider Activity Could Benefit ACI Worldwide Inc (ACIW) - Knox Daily
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - Yahoo Finance
A company insider recently sold 7,662 shares of S&P Global Inc [SPGI]. Should You Sale? - Knox Daily
BeiGene's SVP sells shares worth nearly $285k - Investing.com
BeiGene's SVP sells shares worth nearly $285k By Investing.com - Investing.com UK
BeiGene executive sells over $1.1m in company shares By Investing.com - Investing.com South Africa
BeiGene executive sells over $1.1m in company shares - Investing.com India
BeiGene stock soars to 52-week high, touches $220 mark - Investing.com
A company insider recently sold 24 shares of Phreesia Inc [PHR]. Should You Sale? - Knox Daily
BeiGene adds new board member with financial expertise - Investing.com
BeiGene executive Wu Xiaobin sells over $1 million in company stock - Investing.com India
BeiGene (NASDAQ:BGNE) Now Covered by Analysts at JMP Securities - Defense World
JMP calls BeiGene a 'unique investment opportunity', sets $288 shares target By Investing.com - Investing.com
New additions to Roth MKM’s ADR portfolio for September - MSN
Opera Limited Sponsored ADR (OPRA) Crossed Above the 20-Day Moving Average: What That Means for Investors - Yahoo Finance
Checking in on BeiGene Ltd ADR (BGNE) after recent insiders movement - Knox Daily
BeiGene stock touches 52-week high at $211.56 amid market fluctuations - Investing.com
Analyzing Jefferies Financial Group Inc (JEF) After Recent Trading Activity - Knox Daily
VICI Properties Inc [VICI] stock for 201,530 USD was bought by ABRAHAMSON JAMES R - Knox Daily
BeiGene executive sells $26,021 in company stock - Investing.com India
Finanzdaten der Beigene Ltd Adr-Aktie (BGNE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Beigene Ltd Adr-Aktie (BGNE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| OYLER JOHN | Chief Executive Officer |
Oct 08 '24 |
Sale |
232.22 |
6,175 |
1,433,931 |
0 |
1.11%
2.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):